PR Newswire BiotechnologyCodex · 实盘不做把握 6/10不做原因:无可交易标的
北京时间·🕒 发布 20:15:00·⟳ 抓取 20:15:26 +26s·⚡ 决策 08-27 20:45:51 +30m25s·61.0 天前
Psilera任命临床开发副总裁推进PSIL-006一期临床准备
事件主体Psilera未发现上市交易载体；可映射的公开上市合作方与本次PSIL-006人事任命缺少直接经济权益和量级传导，不能形成正期望交易。
📄 原文PR Newswire Biotechnology↗ 原文
Key appointment strengthens operational leadership as Psilera prepares its lead neuroplastogen, PSIL-006, for clinical-…
不做 Psilera Inc.（N/A）
Psilera为私营早期生物医药公司，未发现可交易证券；本次只是临床开发高管任命，缺少可量化业绩增量和上市公司直接权益映射。
不做 Atai Life Sciences（ATAI.US）
与Psilera的公开关系主要是DMT专利组合授权，当前PSIL-006一期临床人事任命未坐实对Atai有新增收入、里程碑或资产价值增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是一条Psilera推进PSIL-006一期临床准备的人事任命新闻，方向上有助于执行临床开发，但不是临床批准、试验启动、数据读出、融资或商业化合同。Psilera为私营公司，历史融资资料也指向早期私募和NIH资助；Atai相关披露对应的是DMT专利组合授权，并非PSIL-006本次临床任命。缺少可交易主体和可量化增量，因此不做。
消息传播链
- Psilera发布任命Allyson Gage为临床开发副总裁的公司新闻稿，事件为公司自发一手披露。
关键理由
- 本次仅是临床开发负责人任命，说明PSIL-006进入临床准备期，但新增事实离商业化和可量化收入仍远。
- Psilera此前披露的880万美元种子轮和NIH资助已覆盖推进PSIL-006进入临床的背景，本次任命更多是执行层补强。
- Atai相关公开披露指向DMT专利组合授权及里程碑/销售付款，不足以把PSIL-006人事任命映射为Atai的短线交易催化。
主要风险
- 若后续出现IND正式获批、一期试验注册或与上市公司签订明确金额合作，需重新评估可交易映射。
- 本轮无法调用stock_tools验证行情、内部去重、案例库和event_study，因此结论基于公开网页核验而非完整生产工具链。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
未发现Psilera上市证券；Atai披露关系与DMT专利组合相关，削弱把本次PSIL-006人事任命映射为Atai交易催化的理由。
检索:Psilera publicly traded ticker PSIL-006 Atai license SEC 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足没有改变结论；核心否决点仍是无直接可交易资产及缺少上市公司经济权益传导。
方向:未能形成可交易标的前，管理层任命类先例对当前交易方向没有可迁移定价价值。
涨幅量级:无可用同市场、同机制、同交易标的先例校准幅度。
形态:早期私营生物医药公司临床开发高管任命通常更偏融资与运营里程碑，不等同上市公司短线重估催化。
原文全文
展开原文 · 2,753 字
Key appointment strengthens operational leadership as Psilera prepares its lead neuroplastogen, PSIL-006, for clinical-stage evaluation.
TAMPA, Fla., Aug. 27, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the appointment of Allyson Gage, PhD, as Vice President, Clinical Development. In this role, Dr. Gage will oversee the clinical development strategy and operational execution of the upcoming Phase 1 first-in-human clinical trials of Psilera's lead asset, PSIL-006.
Dr. Gage brings over 25 years of experience to Psilera, with a track record of advancing numerous compounds through FDA IND approval. Her expertise in biomarker identification and evaluation in CNS indications, small molecules, biologics, and cell therapies ideally positions her to lead Psilera's Phase 1 trial as VP, Clinical Development.
"Psilera is engineering tomorrow's therapies by leveraging the potential therapeutic power of neuroplastogens," states Dr. Gage. "I'm honored to join this team and to help guide PSIL-006 through the clinical milestones that will bring these treatments to the patients who need them."
The PSIL-006 Phase 1a clinical trial will evaluate safety, tolerability, and key biomarkers in human subjects, supporting its development for neuropsychiatric conditions such as depression, addiction, PTSD, and neurodegeneration. The trial follows significant corporate momentum for Psilera, including the close of an $8.8M oversubscribed seed funding round, key strategic partnerships, and institutional backing from the NIH through grant funding for IND-enabling studies.
"I am thrilled to partner with Dr. Gage once again as we advance the neuroplastogen pipeline at Psilera," expressed Magali Haas, MD-PhD, CMO of Psilera. "Allyson brings an exceptional combination of CNS drug development expertise and leadership with her impressive track record navigating the complex path from first-in-human studies through pivotal trials and ultimately regulatory approval."
About PSIL-006
PSIL-006 is a first-in-class neuroplastogen designed to harness the rapid therapeutic benefits of traditional psychedelics while reducing limiting factors such as clinic visits and hallucinations. Through Psilera's proprietary computational discovery platform, Psilera Third Eye ™, PSIL-006 has been engineered as a selective agonist at key serotonin receptors (5-HT2A, 5-HT2C, and 5-HT6) with a unique profile, enabling scalable, take-home dosing.
Learn more by visiting www.psilera.com.
Contact Information:
Investors: Monique Kosse, Gilmartin Group
[email protected]
Media: Katie DeMarsh, Director of Marketing
[email protected]
SOURCE Psilera, Inc.
TAMPA, Fla., Aug. 27, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the appointment of Allyson Gage, PhD, as Vice President, Clinical Development. In this role, Dr. Gage will oversee the clinical development strategy and operational execution of the upcoming Phase 1 first-in-human clinical trials of Psilera's lead asset, PSIL-006.
Dr. Gage brings over 25 years of experience to Psilera, with a track record of advancing numerous compounds through FDA IND approval. Her expertise in biomarker identification and evaluation in CNS indications, small molecules, biologics, and cell therapies ideally positions her to lead Psilera's Phase 1 trial as VP, Clinical Development.
"Psilera is engineering tomorrow's therapies by leveraging the potential therapeutic power of neuroplastogens," states Dr. Gage. "I'm honored to join this team and to help guide PSIL-006 through the clinical milestones that will bring these treatments to the patients who need them."
The PSIL-006 Phase 1a clinical trial will evaluate safety, tolerability, and key biomarkers in human subjects, supporting its development for neuropsychiatric conditions such as depression, addiction, PTSD, and neurodegeneration. The trial follows significant corporate momentum for Psilera, including the close of an $8.8M oversubscribed seed funding round, key strategic partnerships, and institutional backing from the NIH through grant funding for IND-enabling studies.
"I am thrilled to partner with Dr. Gage once again as we advance the neuroplastogen pipeline at Psilera," expressed Magali Haas, MD-PhD, CMO of Psilera. "Allyson brings an exceptional combination of CNS drug development expertise and leadership with her impressive track record navigating the complex path from first-in-human studies through pivotal trials and ultimately regulatory approval."
About PSIL-006
PSIL-006 is a first-in-class neuroplastogen designed to harness the rapid therapeutic benefits of traditional psychedelics while reducing limiting factors such as clinic visits and hallucinations. Through Psilera's proprietary computational discovery platform, Psilera Third Eye ™, PSIL-006 has been engineered as a selective agonist at key serotonin receptors (5-HT2A, 5-HT2C, and 5-HT6) with a unique profile, enabling scalable, take-home dosing.
Learn more by visiting www.psilera.com.
Contact Information:
Investors: Monique Kosse, Gilmartin Group
[email protected]
Media: Katie DeMarsh, Director of Marketing
[email protected]
SOURCE Psilera, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。